Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986365 vs Investigator's Choice in mCRPC (rechARge)
NCT06764485Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Mar 2025
- Primary completion
- Sep 2027
- Countries
- 26
01
Overview
A Phase 3 trial of BMS-986365 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Celgene Corporation. Started Mar 2025; status: active, not recruiting.
02
Drugs
BMS-986365
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06764485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06764485.